Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Fentanyl for Breakthrough Cancer Pain
NCT02514252Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fentanyl (transdermal patch + oral transmucosal lozenge) in breakthrough cancer pain (BTcP), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2016; status: terminated.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT02514252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514252.